Nature Reviews Cancer content July 2013 Volume 13 Number 7 pp 437-518

Advertisement
Super Capabilities are Now Within Your Reach. Experience the LightCycler® 96 Instrument's intuitive user interface and powerful analysis software. Innovative optics, cutting-edge thermal resolution and data reproducibility enable research breakthroughs. Find out how to become a scientific Superhero!
TABLE OF CONTENTS
July 2013 Volume 13 Number 7
Impact Factor 37.545 *	In this issue Research Highlights Reviews Perspectives Also this month Article series: Genomic instability in cancer Article series: Epigenetics and genetics  Featured article: Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host Winston Timp & Andrew P. Feinberg
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Webinar on high throughput pharmacogenetic analysis of key ADME/T biomarkers • Wednesday June 26. • Register now for : 8AM PST or 4PM PST • Measurement, analysis and reporting of SNPs, INDELs and CNVs in 36 key genes related to ADME/T including CYP2C9, CYP2C19, CYP2D6, and UGT1A1
RESEARCH HIGHLIGHTS Top Metabolism: Epigenetic links to the web of Krebs p437 | doi:10.1038/nrc3551 Two new studies emphasize links between metabolism and the epigenome by showing that various cancers with mutations in the Krebs cycle enzyme succinate dehydrogenase have a characteristic DNA hypermethylation phenotype. PDF Metabolism: Taking it all in p438 | doi:10.1038/nrc3550 Macropinocytosis by RAS-mutant cells and tumours can supply cells with amino acids that can then be used in metabolic pathways. PDF TRIAL WATCH Immune boost p438 | doi:10.1038/nrc3562 PDF Heterogeneity: A multidimensional overview p439 | doi:10.1038/nrc3549 This paper describes a new method for viewing multidimensional, single-cell mass cytometry data. PDF IN THE NEWS Promise for BRCA-defective cancers p439 | doi:10.1038/nrc3552 A new drug shows promise for patients with triple-negative breast cancer. PDF Metabolism: Metabolic block p440 | doi:10.1038/nrc3547 Two recent papers have provided evidence that the mitochondrial sirtuin SIRT4 exerts tumour suppressive activities by repressing glutamine metabolism. PDF Cell death: A2B via p53 p440 | doi:10.1038/nrc3548 Kevin Ryan and colleagues have identified a new route through which the tumour suppressor protein p53 induces apoptosis. PDF IN BRIEF Inflammation: Mutant p53 fans the flames | Therapeutics: Histone eviction | Metabolism: Desaturated lipids required for survival | Tumour dormancy: A perivascular niche can promote dormancy PDF Cancer JOBS of the week Cancer Research Faculty Position Tulane University 2014 Pancreas Cancer Research Fellowship Virginia Mason Medical Center PhD Project In: Signaling, Stem Cells, Development & Cancer DKFZ - German Cancer Research Center 10 Postdoctoral Fellowships in Cancer Research German Cancer Research Center (DKFZ) More Science jobs from Cancer EVENT Cancer Vaccines 19.09.13 London, UK More science events from
REVIEWS		Top
Article series: Genomic instability in cancer End-joining, translocations and cancer Samuel F. Bunting & Andre Nussenzweig p443 | doi:10.1038/nrc3537 Sequencing approaches have confirmed that numerous, non-clonal translocations are a typical feature of cancer cells. The factors and pathways that promote translocations are becoming clearer, with non-homologous end-joining being implicated as a major source of chromosome rearrangements. Abstract | Full Text | PDF
Decoding and unlocking the BCL-2 dependency of cancer cells Philippe Juin, Olivier Geneste, Fabien Gautier, Stéphane Depil & Mario Campone p455 | doi:10.1038/nrc3538 Cancer cells are subject to many apoptotic stimuli that would kill them were it not for compensatory prosurvival alterations. BCL-2-like (BCL-2L) proteins contribute to such aberrant behaviour. Targeting these proteins is not a new idea, but might still offer therapeutic efficacy if the phenotype of BCL-2L protein dependence is better understood and can be diagnosed by relevant biomarkers. Abstract | Full Text | PDF
MSP-RON signalling in cancer: pathogenesis and therapeutic potential Hang-Ping Yao, Yong-Qing Zhou, Ruiwen Zhang & Ming-Hai Wang p466 | doi:10.1038/nrc3545 This Review outlines evidence supporting a role for macrophage-stimulating protein (MSP) and its receptor RON in cancer progression and discusses the therapeutic potential of targeting this signalling axis. Abstract | Full Text | PDF
Forkhead box proteins: tuning forks for transcriptional harmony Eric W.-F. Lam, Jan J. Brosens, Ana R. Gomes & Chuay-Yeng Koo p482 | doi:10.1038/nrc3539 Forkhead box (FOX) transcription factors fine-tune the spatial and temporal expression of many genes and integrate a multitude of cellular and environmental signals. Several FOX family transcription factors have been implicated in cancer and may be therapeutic targets or putative biomarkers. Abstract | Full Text | PDF | Supplementary information
PERSPECTIVES		Top
OPINION Article series: Epigenetics and genetics Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host Winston Timp & Andrew P. Feinberg p497 | doi:10.1038/nrc3486 Feinberg and Timp review cancer-associated epigenetic alterations and propose that epigenetic dysregulation is an initiating force in tumorigenesis that promotes the selection of cancer-associated phenotypes and that can cooperate with genetic alterations, indicating that the gene-centric view of cancer biology is not the whole story. Abstract | Full Text | PDF
OPINION The evolution of the cancer niche during multistage carcinogenesis Mary Helen Barcellos-Hoff, David Lyden & Timothy C. Wang p511 | doi:10.1038/nrc3536 In this Perspective article, the authors propose that the construction of a 'precancer niche' is a necessary and early step that is required for tumorigenesis. Because a cancer niche would evolve with the transformed cell, cancer niches potentially represent an emergent property of a tumour that could be a robust target for cancer prevention and therapy. Abstract | Full Text | PDF
Corrigendum: Targeting allosteric disulphide bonds in cancer Philip J. Hogg p518 | doi:10.1038/nrc3558 Full Text | PDF
Advertisement
Wondering where to publish your next paper?  Frontiers is a community-oriented open-access publisher and research network. We are driving innovations around peer-review and a whole ecosystem of open science tools  Be a part of the future of research publication
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.